CD274 and cancer: In line with our findings, a meta-analysis evaluating different cancer types suggested that PD-1 inhibitors were associated with a better objective response rate (21.6% versus 17.6%) and duration of response (11.26 versus 10.03 months) compared to PD-L1 inhibitors [29].